Headquartered in Silver Spring, MD Fiscal year ends December NASDAQ: UTHR unither.com
United Therapeutics Corporation is a public benefit corporation focused on the development and commercialization of therapies for rare diseases, particularly pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and idiopathic pulmonary fibrosis (IPF). The company's commercial portfolio includes Tyvaso DPI and Nebulized Tyvaso (inhaled treprostinil), Remodulin (subcutaneous/intravenous treprostinil), Orenitram (oral treprostinil), Unituxin (dinutuximab for high-risk neuroblastoma), and Adcirca (tadalafil for PAH). United Therapeutics is also advancing a pipeline of next-generation therapies including ralinepag (an oral IP receptor agonist) and treprostinil delivered via soft mist inhaler. Beyond pharmaceuticals, the company is pioneering organ manufacturing through xenotransplantation, with clinical trials ongoing or planned for manufactured liver, kidney, heart, and lung products, and xeno-organ production facilities under development in Minnesota and Texas. Updated
A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.
Pre-Market Stock Futures: Futures are trading higher after the bulls charged early Wednesday after the August CPE inflation report came in better than expected. But by the close, the tech-heavy Nasdaq was…
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred by reports that a peace agreement with Iran could be forthcoming soon and by incredible technology earnings and…
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on…
United Therapeutics (NASDAQ:UTHR | UTHR Price Prediction) surged more than 12% in pre-market trading on March 30 after positive TETON-1 trial data triggered price target raises from two major Wall Street firms.…
Joel South Tuesday's top analyst upgrades and downgrades included CrowdStrike, Diamondback Energy, DoorDash, Etsy, JetBlue Airways, Lululemon Athletica, Marriott International and Silvergate Capital.
Tuesday's top analyst upgrades and downgrades included Adobe, Cheniere Energy, CNX Resources, Edwards Lifesciences, EOG Resources, Huntsman, Kraft Heinz, NCR, Peloton Interactive, PulteGroup, Take-Two Interactive Software and UDR.
Tuesday's top analyst upgrades and downgrades included Accenture, Altria, American Airlines, APA, Bumble, Chevron, Datadog, General Motors, Mastercard, Pinduoduo, Regeneron Pharmaceuticals, Tesla, Toast and TotalEnergies.
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic…
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Cree, Etsy, Gilead Sciences, Pfizer, Rite Aid, Solar Edge, Square, 3D Systems and Virgin Galactic.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
The top analyst upgrades, downgrades and initiations on Monday included Apple, Carnival, Generac, Lyft, Six Flags, Square, Tecnoglass, Yum! Brands, Western Digital and Zoetis.
The top analyst upgrades, downgrades and initiations seen on Thursday included American Eagle Outfitters, Atlassian, Match, NextEra Energy, Nordstom, Office Depot, Roku, Stamps.com and Tanger Factory Outlet Centers.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Alcoa, Apple, Autodesk, BB&T, Bed Bath & Beyond, Camping World, Nvidia, Vertex Pharmaceuticals and Voya Financial.
Arena Pharmaceuticals shares jumped early on Thursday after the company announced a new global license agreement with United Therapeutics.
United Therapeutics Corporation is a public benefit corporation focused on the development and commercialization of therapies for rare diseases, particularly pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and idiopathic pulmonary fibrosis (IPF).
24/7 Wall St.'s 12-month price target for UTHR is $682.60, rated Buy. The Wall Street consensus target is $649.64. UTHR price prediction →
